Cardiac Screening Test May Help Determine Who Should Take Aspirin to Prevent Heart Attack
A study involving the Minneapolis Heart Institute Foundation shows that a simple test to measure plaque in the arteries of the heart may help doctors better determine who will and will not benefit from use of aspirin therapy to prevent heart disease.
For over 30 years, aspirin has been known to prevent heart attacks and strokes, but who exactly should take a daily aspirin remains unclear. New research published today in Circulation: Cardiovascular Quality and Outcomes shows that your coronary artery calcium (CAC) score, a measurement of plaque in the arteries that feed the heart, may help determine whether or not you are a good candidate for aspirin.
“Many heart attacks and strokes occur in individuals who do not appear to be at high risk,” states lead author, Michael D Miedema, MD, MPH. “Individuals with known CVD [cardiovascular disease] should take a daily aspirin, but the best approach for individuals without known CVD is unclear.
If we only treat high-risk individuals with aspirin, we are going to miss a substantial portion of patients who eventually suffer heart attacks. However, liberally prescribing aspirin increases the bleeding risk for a significant number of people who were never going to have a heart attack in the first place. With this study, we wanted to see if there is potentially a better way to determine who to treat with aspirin beyond simply using traditional risk factors.”
Aspirin helps prevent heart attacks and strokes by preventing blood clots from forming in arteries lined with unhealthy plaque buildup. However, this same benefit puts patients taking aspirin at risk for dangerous bleeding, when blood clots don’t form where they should. For that reason, the American Heart Association (AHA) guidelines currently recommend aspirin to prevent cardiovascular disease (CVD) in people who have known CVD or who are considered to be at high risk for a CVD event. Aspirin is generally not recommended for people who are considered to be at low or intermediate risk.
In this retrospective study, researchers studied 4,229 participants in the Multi-Ethnic Study of Atherosclerosis (MESA) from six centers across the country. Participants included had no known CVD or diabetes, were not on aspirin therapy, and were followed for approximately 7 years.
Participants were grouped according to their CAC score and the rates of heart attacks in each group were calculated. Based on these rates, the research team weighed the likelihood of an individual to benefit from aspirin therapy (the potential of the aspirin to prevent a heart attack) against the likelihood of harm (the potential for the aspirin to cause major bleeding).
They estimated that participants with elevated CAC scores (>100) were 2−4 times more likely to benefit from aspirin therapy than to be harmed, even if they did not qualify for aspirin use according to current AHA guidelines. Conversely, MESA participants with no calcified plaque (CAC score = 0) were 2−4 times more likely to be harmed by aspirin use than to benefit. The results in both groups held true even after accounting for traditional risk factors.
“We estimate that individuals with significant plaque buildup in the arteries of the heart are much more likely to prevent a heart attack with aspirin use than to suffer a significant bleed” explains Miedema. “On the opposite end of the spectrum, if you don’t have any calcified plaque, our estimations indicate that use of aspirin would result in more harm than good, even if you have risk factors for heart disease such as high cholesterol or a family history of the disease.”
Miedema added, “A CAC score of zero is associated with a very low risk of having a heart attack. That means individuals with a score of zero may not benefit from preventive medications, such as aspirin as well as the cholesterol-lowering statin medications. Approximately 50% of middle-aged men and women have a CAC score of zero, so there is a potential for this test to personalize the approach to prevention and allow a significant number of patients to avoid preventive medications, but we need further research to verify that routine use of this test is the best option for our patients.”
Michael Miedema is a preventative cardiologist at the Minneapolis Heart Institute® at Abbott Northwestern Hospital and a clinical investigator with the Minneapolis Heart Institute Foundation (MHIF). The full study results are published in Circulation: Cardiovascular Quality and Outcomes HERE.
Jackie Boucher | Eurek Alert!
Modeling NAFLD with human pluripotent stem cell derived immature hepatocyte like cells
30.06.2016 | Heinrich-Heine University Duesseldorf
Heat for wounds – water-filtered infrared-A (wIRA) assists wound healing
30.06.2016 | Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften
Since the completion of the human genome an important goal has been to elucidate the function of the now known proteins: a new molecular method enables the investigation of the function for thousands of proteins in parallel. Applying this new method, an international team of researchers with leading participation of the Technical University of Munich (TUM) was able to identify hundreds of previously unknown interactions among proteins.
The human genome and those of most common crops have been decoded for many years. Soon it will be possible to sequence your personal genome for less than 1000...
3D printing revolutionized the manufacturing of complex shapes in the last few years. Using additive depositing of materials, where individual dots or lines...
R2D2, a joint project to analyze and development high-TRL processes and technologies for manufacture of flexible organic light-emitting diodes (OLEDs) funded by the German Federal Ministry of Education and Research (BMBF) has been successfully completed.
In contrast to point light sources like LEDs made of inorganic semiconductor crystals, organic light-emitting diodes (OLEDs) are light-emitting surfaces. Their...
High resolution rotational spectroscopy reveals an unprecedented number of conformations of an odorant molecule – a new world record!
In a recent publication in the journal Physical Chemistry Chemical Physics, researchers from the Max Planck Institute for the Structure and Dynamics of Matter...
Strands of cow cartilage substitute for ink in a 3D bioprinting process that may one day create cartilage patches for worn out joints, according to a team of engineers. "Our goal is to create tissue that can be used to replace large amounts of worn out tissue or design patches," said Ibrahim T. Ozbolat, associate professor of engineering science and mechanics. "Those who have osteoarthritis in their joints suffer a lot. We need a new alternative treatment for this."
Cartilage is a good tissue to target for scale-up bioprinting because it is made up of only one cell type and has no blood vessels within the tissue. It is...
30.06.2016 | Event News
28.06.2016 | Event News
09.06.2016 | Event News
30.06.2016 | Health and Medicine
30.06.2016 | Life Sciences
30.06.2016 | Physics and Astronomy